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Abstract
Cardiac transplantation (TxC) is considered the first therapeutic option in patients with 
congestive heart failure, refractory to clinical treatment and without the possibility of 
conventional surgical treatment. The pathophysiological status, as a consequence of 
severe cardiomyopathy, is represented by various degrees of systolic and diastolic dys-
function, reflecting low ejection volumes and high diastolic volumes and high filling 
diastolic pressures, respectively. Patients in this pathophysiological context also present, 
among other symptoms, neurohormonal alterations of the renin-angiotensin aldosterone 
system, decreased renal, visceral and splanchnic perfusion, and increased levels of cat-
echolamines. Barnard et al., in 1967, performed the first orthotopic heart transplantation 
among humans with relative success, Zerbini (1969) being the first to perform it in Brazil. 
The presence of high rates of graft rejection and infection accounted for small survival 
and caused great disinterest and abandonment of the technique in the 70’s. However, 
the experience accumulated by the groups that maintained TxC as a treatment, mainly 
after the introduction of cyclosporin A, first in kidney transplantation in 1978, and in 
1980 in TxC, reinvigorated this therapeutic option, allowing the true development and 
the application of this treatment worldwide.
Keywords: nanoemulsions, methotrexate, paclitaxel, heart transplantation, 
allograftvasculopathy
1. Introduction
Cardiac transplantation (TxC) is currently considered the first therapeutic option in patients 
with congestive heart failure, refractory to clinical treatment and without the possibility of 
conventional surgical treatment [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The pathophysiological status, as a consequence of severe cardiomyopathy, is represented 
by various degrees of systolic and diastolic dysfunction, reflecting low ejection volumes and 
high diastolic volumes and high filling diastolic pressures, respectively [2].
Patients in this pathophysiological context also present, among other symptoms, neurohor-
monal alterations of the renin-angiotensin aldosterone system, decreased renal, visceral, and 
splanchnic perfusion, and increased levels of catecholamines.
The first reference for heart transplantation is from Carrel and Guthrie, who performed the trans-
plantation of an young animal’s heart on the neck of an adult animal [3]. It was, however, the work 
of Lower and Shumway in the 1950s and 1960s that standardized the technique—which provided 
a long survival for dogs with immunosuppression—and laid the foundations for the success of 
this surgical treatment. Barnard et al., in 1967, performed the first orthotopic heart transplantation 
among humans with relative success, Zerbini being the first to perform it in Brazil [4].
The presence of high rates of graft rejection and infection accounted for small survival and 
caused great disinterest and abandonment of the technique in the 70’s [5, 6]. However, the 
experience accumulated by the groups that maintained TxC as a treatment, mainly after the 
introduction of cyclosporin A, first in kidney transplantation in 1978, and in 1980 in TxC, 
reinvigorated this therapeutic option, allowing the true development and the application of 
this treatment worldwide.
2. Type of rejection in cardiac transplantation
2.1. Acute cellular rejection
In acute cellular rejection, the antigen-presenting cells directly or indirectly carry the immune 
message of the graft to the T lymphocyte in a phenomenon known as allorecognition. In 
this process, the T lymphocyte membrane is bombarded by multiple immune stimuli that 
activate different effectors, especially calcineurin, which, through interleukin-2, promotes the 
clonal expansion of T lymphocytes, leading to the production of the following cell clones and 
enzymes [7, 8].
Auxiliary T lymphocytes (CD4—Helper T lymphocytes) identify antigens on the membrane 
of cells that have been phagocytosed by macrophages and thereby activate the body’s specific 
immunity;
Cytotoxic T lymphocytes (CD8—Killer T lymphocytes) have the ability to induce lysis of tar-
get cells to the case in point the graft cells;
Lymphocytes B are responsible for humoral immunity due to the production of antibodies 
against foreign antigens, which may give rise to plasma cells (antibody producing cells) or 
memory cells.
Natural cytotoxic cells (natural killer cells) are granular lymphocytes that destroy target cells 
by adherence, similar to cytotoxic T lymphocytes (CD8); and the proliferation or rapamycin 
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target enzyme (mTOR—target of rapamycin) regulates the transcription of messenger RNA, 
acting on growth, proliferation, motility, survival, and protein synthesis of the lymphocyte.
Immunosuppression is generally based on regimens of induction, maintenance, and treat-
ment of acute rejection, described below:
The induction regimen seeks to achieve and induce graft tolerance. This therapy has been 
reserved for patients at high risk of rejection or renal failure.
• Maintenance therapy usually consists of a therapy combination of corticosteroids, antipro-
liferative agents, and calcineurin inhibitors. Combination drug therapy seeks to achieve the 
activation of T cell lymphocytes at various stages, thus allowing lower doses of each drug.
• Rejection or rescue therapy refers to immunosuppressive therapy used to reverse an epi-
sode of acute rejection. Rejection is treated by increasing oral therapy with pulses of oral or 
intravenous corticosteroids with changes in oral therapy or with the use of monoclonal or 
polyclonal antilymphocytic agents.
2.2. Antibody-mediated rejection
Antibody-mediated rejection can be understood as another form of immune reaction that has 
a generally more severe course, since circulating preformed antibodies already exists against 
the alloantigens of the HLA (human leukocyte antigens) graft system. It is a catastrophic 
situation that leads to acute dysfunction of the organ, and immunosuppressors cannot exert 
any immediate effect [9–11]. As a preventive measure to curb this event, it has been advocated 
prior knowledge of the reactivity of the receptor potential to a panel of lymphocytes and 
the prospective knowledge of cross-lymphocyte testing. In this way, it becomes possible to 
allocate the donated hearts more rationally to the most suitable recipients.
3. Graft vascular disease
Graft vascular disease in cardiac transplantation is an insidious complication, characterized 
by persistent perivascular inflammation and intimal hyperplasia. It was first described by 
Thomson, 1969, and emerges as the most important factor affecting long-term survival after 
transplantation [12].
Graft vascular disease and coronary atherosclerosis are atheromatous diseases with some simi-
larities and differences in macroscopic and microscopic presentation. Both diseases are charac-
terized by increased cell adhesion and leukocyte infiltration, similar environment and cytokine 
profiles, aberrant extracellular matrix, and early and prolonged accumulation of extracellular 
and intracellular lipids, as well as migration of smooth muscle cells, endothelial dysfunction, 
and abnormality in cellular apoptosis.
It represents a type of rejection in which aggression immune to the coronary endothelium 
occurs persistently and constitutes the main late complication, limiting the survival of the 
patient and the graft itself in the long term [13].
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Although acute graft failure after transplantation has improved over the last two decades, 
the same cannot be said in the long run where achievements have been less pronounced. 
Graft vascular disease appears as the main complication after the first year of transplanta-
tion and lacks specific and effective therapy. The importance of this entity can be observed 
in the comparative analysis of the survival curves presented by the International Society 
for Heart and Lung Transplantation, in which patients who developed vasculopathy had 
a higher mortality rate than the others.13 The graft vascular disease is responsible for 17% 
of the deaths and can be detected as early as the first year after transplantation, reaching in 
the third year figures in the order of 42% by cinecoronariography and 75% by intravascular 
ultrasonography [13–17].
The “graft vascular disease” designation has received greater acceptance rather than the other 
ones—post-transplant atherosclerosis, chronic rejection, accelerated atherosclerosis, graft vas-
culopathy and others—because it expresses more appropriately the immunological phenom-
enon that is common to transplants of solid organs [9].
Graft vascular disease is a form of accelerated coronary vasculopathy of immune origin that 
has not yet been completely clarified, in which nonimmunological factors also take place. 
However, the most likely entrance door is the endothelial dysfunction, as it allows the aggres-
sion of the subintimal layer and stimulates the myointimal proliferation in the wall of the 
artery. The inflammatory process extends to the entire arterial bed and, occasionally, to the 
veins, sparing only the recipient’s native vessels [8, 18].
In the initial phase of the lesion, there is a discrete thickness of the intima, with little hyper-
plastic fibrosis and an increase in extracellular matrix proteins. At this stage, the internal elas-
tic lamina is still intact, and the involvement is limited to the proximal arteries. Subsequently, 
the thickness proceeds diffusely through the coronary vasculature, with the appearance of 
plaques of fibroadiposal tissue and gradual deposition of calcium with the future formation 
of isolated plaques of atheroma [19, 20]. The first intimal changes can be observed as early as 
the sixth month after transplantation [15, 16, 19].
In the late phase of the disease, it is observed that the thickness of the intima is diffuse, with 
hyperplasia and concentric fibrosis. A detailed study of the coronary arteries has shown the 
incorporation of lipids and focal plaques of atheromas interspersed with diffuse arteritis 
[19, 20]. The arteries thickness occurs by the infiltration of mononuclear inflammatory cells 
in response to alloimmune stimuli or by infection, and in this last situation, the participation 
of the cytomegalovirus deserves special attention. In a more advanced stage, the medial 
layer may be totally or partially replaced by fibrous tissue. Only vessels with little or no 
muscle layer can be spared [21–23].
The participation of acute rejection is controversial in the development of graft vascular dis-
ease [24–26]. Among the nonimmunological factors considered to be at risk for graft vascular 
disease, we highlight those that may compromise the integrity of the endothelium, as classi-
fied below [24–29]:
The donor risk factors encephalic death etiology, age, sex, atherosclerotic disease, and his or 
her clinical characteristics.
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As for the receptor: age, sex, cytomegalovirus infection, diabetes mellitus, hypertension, dys-
lipidemia, smoking, obesity, and hyperhomocysteinemia. Among these are hyperlipidemia 
and diabetes mellitus with incidence between 50 and 80%.
The first step in triggering graft vascular disease is the recognition that occurs after reperfusion 
of the graft, aggravated by postanoxic endothelial dysfunction. The major cytokines involved in 
the rejection process are interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor 
alpha (TNF-α). IL-2 induces proliferation and differentiation of T lymphocytes; IFN-γ activates 
the macrophages; and TNF-α alone is cytotoxic to the transplanted heart. In addition, TNF-α 
increases the expression of MHC class I molecules, whereas IFN-γ increases MHC expression of 
both classes I and II. In general, these cytokines may lead to chronic rejection of the graft. IFN-γ and 
TNF-α induce the production of vascular cell adhesion molecule 1 (VCAM-1), promoting mono-
cyte adhesion and passage through the endothelium and, consequently, vascular graft disease. 
Explosive encephalic death promotes greater release of cytokines and adhesion molecules and 
increases the expression of class I and II antigens of the MHC system, promoting an inflammatory 
reaction exacerbated in the heart of the potential donor and leading to endothelial dysfunction.
The clinical diagnosis of graft vascular disease is difficult, since myocardial ischemia presents 
a silent course because it is a denervated heart. In the advanced stage, the disease often mani-
fests with signs of heart failure, arrhythmias or even sudden death [14, 21, 30–32].
Coronary angiography may not express the true severity of the graft vascular disease, since 
the examination allows only the analysis of the internal diameter of the artery and not of 
the wall [29, 31–33]. It has been proposed to complement the examination with intravascular 
ultrasonography, which allows to detect the coronary artery wall thickness even in the initial 
phase of the process. However, this method is not yet widely used, it is invasive and is limited 
to analysis only of the largest caliber arteries.
Regarding the noninvasive methods, the dobutamine stress echocardiogram has shown 
advantages as a non-invasive screening test with good sensitivity to select patients with a 
higher risk of graft vascular disease [13, 34–36].
Among the alternative surgical methods, direct myocardial revascularization or angioplasty 
deserves special mention, although both present serious restrictions due to the universal dis-
tribution of inflammation in the arteries; therefore, the prognosis of the disease is bleak, and 
few patients can benefit from retransplantation [31, 37, 38].
Ultimately, effective treatment of graft vascular disease in humans is nonexistent, simply lim-
iting the use of prophylactic measures to reduce risk factors. In this way, the treatment of this 
terrible disease constitutes a fertile field of research but with multiple challenges.
4. Nanotechnology and nanoscience
Nanotechnology and nanoscience, ranging from 1 to 100 nanometers (nm), focus on materials 
of atomic size, molecular, and supramolecular, which point to the control and manipulation 
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of these new materials precisely by configuring atoms and molecules, producing new molec-
ular aggregates and designing self-aggregation systems to create supramolecular devices at 
the cellular or minor scale.
The nanoscale is prevalent in natural systems, as several functional components of living cells 
fit into this anthropometric classification, but few drugs or diagnostic, therapeutic, and repair 
devices have been developed on this scale.
The properties of the nanoscale allow high density of function in small packages to minimize 
invasiveness and facilitate intelligent therapeutic interventions with increased specificity of 
release and action, decrease of side effects, and ability to respond to external stimuli and to 
refer to external receptors.
Nanotechnology and nanomedicine are two areas of great growth that have provided new 
diagnostic and therapeutic opportunities for cardiovascular, pulmonary, hematological, and 
sleep diseases. In the near future, nanotechnology will play an increasingly significant role in 
the day-to-day practice of cardiologists, pneumonologists, and hematologists.
The use of nanoparticles in medicine was first performed in the treatment of cancer and pro-
gressed rapidly, being well used to address the limitations of conventional drug delivery 
systems, such as nonspecific and target biodistribution, water solubility, poor oral bioavail-
ability, and low therapeutic indexes.
An effective way to achieve drug delivery efficiency will be to reasonably develop nanosys-
tems based on their knowledge of their interactions with the biological environment, target 
cell population, changes in cellular receptors that occur with disease progression, mechanism 
and site of drug action, drug retention, multiple drug administration, molecular mechanism, 
and pathobiology of the disease under consideration [39].
In the area of biomedical nanotechnology, the group led by Maranhão has made pioneering 
contributions in the world: they described the first system of nanoparticles (non liposomal) 
produced in the laboratory, capable of directing and concentrating drugs at the drug targeting 
site for treatment for the treatment of proliferative diseases such as cancer and atherosclerosis 
[21, 40, 41] (Pictures 1 and 2).
A fascinating field of impact applications has been opened with the discovery that LDE, 
after injection into the circulatory system, is concentrated in the tumor tissues and can be 
used in the treatment of cancer as a vehicle to direct chemotherapeutics to the neoplastic 
cells [42]. The cell probably due to the need for greater lipid content required by accelerated 
proliferation has a marked increase in the expression of LDL receptors. This enables the use 
of LDE as a vehicle to concentrate neoplastic neoplastic tissue associated with the particles. 
Chemotherapeutics are thus diverted from the normal tissues of the organism. Thus, it is 
possible to increase the therapeutic efficacy of these agents and to reduce the side effects 
that constitute an important limitation to chemotherapy. The initial finding was described 
in patients with acute myelocytic leukemia, [40, 41] in whom overexpression of receptors 
reached up to 100-fold. More recently, it has been found that LDE can also be concentrated 
in tissues where there are nonneoplastic proliferative processes [43]. Then, in rabbits with 
Heart Transplantation176
cholesterol-induced diet atherosclerosis, the inflammatory process in atherosclerosis also led 
to the concentration of nanoemulsion in injured arteries. These findings broadened the range 
of potential applications of nanoemulsion as a drug vehicle not only in neoplasias but also in 
atherosclerosis and other chronic inflammatory processes.
The incorporation and stability of drugs within the LDE were optimized with drug modifica-
tion without loss of pharmacological effect. Thus, with the modification of these drugs, it was 
possible to proceed with the assembly of a therapeutic arsenal associated with nanoemulsions. 
Picture 1. Structure of low density lipoprotein (LDL). Modified from www.foodspace.wordpress.com
Picture 2. Structure of lipid nanoemulsion (LDE). Modified from www.foodspace.wordpress.com
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LDE preparations, associated with modified forms of etoposide chemotherapeutic agents, 
paclitaxel 18 and methotrexate, are ready and efficiently tested in vitro and in vivo. In all 
cases, comparing these associations with nanoemulsions to the respective commercial prepa-
rations, a greater therapeutic action at higher doses was shown in culture of neoplastic cells 
and models of tumors implanted in animals (Walker’s tumor and B-16 melanoma). In clinical 
trials with carmustine, etoposide, and paclitaxel [18, 20, 42], it was found that in the use of 
these drugs associated with LDE, even at higher doses than those usually used in the clinic, 
the toxicity was practically absent.
The results described above then directed us to the application of these nanoemulsions in 
the treatment of patients with heart transplantation, in which two main problems predomi-
nate: rejection of the receptor to the transplanted organ and the SVD. These are two enti-
ties that are difficult to manage clinically, which seriously compromise the success of heart 
transplants and which require new therapeutic solutions. For DVE, in general, there is no 
conventional treatment, only retransplantation. The inflammatory and proliferative bases 
of SVD are similar to those of atherosclerotic cardiovascular disease. Thus, the fact that an 
antiproliferative agent associated with LDE has been effective in promoting the regression 
of experimental atherosclerosis suggests that it is equally efficient as a therapeutic approach 
to PVD.
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